Aura Biosciences (AURA) Competitors $6.55 +0.08 (+1.24%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$6.55 0.00 (0.00%) As of 08/22/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA vs. ETNB, EWTX, WVE, ABCL, HROW, VERA, ARDX, COGT, AVDL, and CVACShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include 89BIO (ETNB), Edgewise Therapeutics (EWTX), WAVE Life Sciences (WVE), AbCellera Biologics (ABCL), Harrow (HROW), Vera Therapeutics (VERA), Ardelyx (ARDX), Cogent Biosciences (COGT), Avadel Pharmaceuticals (AVDL), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Its Competitors 89BIO Edgewise Therapeutics WAVE Life Sciences AbCellera Biologics Harrow Vera Therapeutics Ardelyx Cogent Biosciences Avadel Pharmaceuticals CureVac Aura Biosciences (NASDAQ:AURA) and 89BIO (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends. Do insiders & institutionals hold more shares of AURA or ETNB? 96.8% of Aura Biosciences shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by company insiders. Comparatively, 2.6% of 89BIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is AURA or ETNB more profitable? Aura Biosciences' return on equity of -64.44% beat 89BIO's return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -64.44% -54.24% 89BIO N/A -94.48%-80.92% Does the media refer more to AURA or ETNB? In the previous week, Aura Biosciences had 11 more articles in the media than 89BIO. MarketBeat recorded 14 mentions for Aura Biosciences and 3 mentions for 89BIO. 89BIO's average media sentiment score of 0.84 beat Aura Biosciences' score of 0.59 indicating that 89BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 89BIO 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, AURA or ETNB? Aura Biosciences is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$86.92M-$1.96-3.3489BION/AN/A-$367.08M-$3.61-2.61 Do analysts recommend AURA or ETNB? Aura Biosciences currently has a consensus price target of $22.00, suggesting a potential upside of 235.88%. 89BIO has a consensus price target of $26.29, suggesting a potential upside of 178.75%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aura Biosciences is more favorable than 89BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.1189BIO 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility & risk, AURA or ETNB? Aura Biosciences has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, 89BIO has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. SummaryAura Biosciences beats 89BIO on 10 of the 13 factors compared between the two stocks. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$401.92M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-3.3420.8831.1026.05Price / SalesN/A342.78433.22103.03Price / CashN/A43.1937.7358.48Price / Book2.338.129.536.61Net Income-$86.92M-$54.72M$3.26B$265.56M7 Day Performance-2.53%2.63%2.10%1.97%1 Month Performance-6.43%2.78%2.81%-0.36%1 Year Performance-13.70%11.01%30.56%19.03% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences1.8824 of 5 stars$6.55+1.2%$22.00+235.9%-11.4%$401.92MN/A-3.3450Analyst UpgradeETNB89BIO2.0198 of 5 stars$8.77-4.3%$26.29+199.7%+11.3%$1.34BN/A-2.4340EWTXEdgewise Therapeutics2.5965 of 5 stars$12.99+2.4%$41.60+220.2%-24.2%$1.34BN/A-8.3860Analyst ForecastWVEWAVE Life Sciences4.7948 of 5 stars$8.10+0.1%$20.27+150.2%+83.9%$1.29B$108.30M-9.00240Positive NewsABCLAbCellera Biologics2.2936 of 5 stars$4.50+5.9%$8.00+77.8%+74.9%$1.27B$28.83M-8.18500Gap UpHROWHarrow3.6473 of 5 stars$33.74-2.0%$63.83+89.2%-5.3%$1.26B$199.61M-60.25180Analyst RevisionHigh Trading VolumeVERAVera Therapeutics3.7509 of 5 stars$20.17+1.9%$63.00+212.3%-42.3%$1.26BN/A-5.6340Positive NewsARDXArdelyx4.3303 of 5 stars$5.40+3.6%$11.50+113.0%+1.0%$1.26B$333.61M-23.4890Positive NewsCOGTCogent Biosciences3.6446 of 5 stars$10.93-0.3%$18.70+71.1%+24.7%$1.25BN/A-6.1480Positive NewsAVDLAvadel Pharmaceuticals2.7256 of 5 stars$12.79+0.3%$18.67+45.9%-5.8%$1.23B$169.12M-426.3370Analyst ForecastCVACCureVac4.6563 of 5 stars$5.43-0.2%$6.83+25.8%+70.5%$1.22B$579.18M5.90880News CoverageEarnings ReportShort Interest ↓ Related Companies and Tools Related Companies 89BIO Competitors Edgewise Therapeutics Competitors WAVE Life Sciences Competitors AbCellera Biologics Competitors Harrow Competitors Vera Therapeutics Competitors Ardelyx Competitors Cogent Biosciences Competitors Avadel Pharmaceuticals Competitors CureVac Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AURA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access